Quels nouveaux fibrinolytiques ? = Which new thrombolytics ?ALESSI, M.-C.STV. Sang thrombose vaisseaux. 2000, Vol 12, Num 6, pp 371-377, issn 0999-7385Article

Le système fibrinolytique : activation et inhibition. ses modifications en cas de CIVD = Fibrinolysis: activation and inhibition. Its modification during DICALESSI, M. C.Réanimation (Paris. 2001). 2002, Vol 11, Num 8, pp 591-598, issn 1624-0693, 8 p.Article

Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseasesMAVRI, A; ALESSI, M.-C; JUHAN-VAGUE, I et al.Journal of internal medicine. 2004, Vol 255, Num 4, pp 448-456, issn 0954-6820, 9 p.Article

Vieillissement de la paroi artérielle : endothélium, thrombose et fibrinolyse = Ageing of the artery wall. Endothelium, thrombosis and fibrinolysisJUHAN-VAGUE, I; ALESSI, M. C.Annales de cardiologie et d'angéiologie (Paris). 1991, Vol 40, Num 5, pp 243-247, issn 0003-3928, 5 p.Conference Paper

TAFI : lien moléculaire entre les processus de coagulation et de fibrinolyse = TAFI : a molecular link between the processes of coagulation and fibrinolysisJUHAN-VAGUE, I; ALESSI, M.-C.STV. Sang thrombose vaisseaux. 1998, Vol 10, Num 5, pp 314-316, issn 0999-7385Article

Endothélium, thrombose et fibrinolyse : Endothélium = Endothelium, thrombosis and fibrinolyses : EndotheliumALESSI, M.-C; JUHAN-VAGUE, I.La Revue du praticien (Paris). 1997, Vol 47, Num 20, pp 2227-2231, issn 0035-2640Article

Thrombolytiques et leur maniement : Médicaments antithrombotiques = Description and use of thrombolytic drugsALESSI, M.-C; JUHAN-VAGUE, I.La Revue du praticien (Paris). 1999, Vol 49, Num 15, pp 1654-1658, issn 0035-2640Article

Contribution of PAI-1 in cardiovascular pathologyALESSI, M. C; JUHAN-VAGUE, I.Archives des maladies du coeur et des vaisseaux. 2004, Vol 97, Num 6, pp 673-678, issn 0003-9683, 6 p.Article

Fibrinolyse et diabète sucré = Fibrinolysis and diabetesJUHAN-VAGUE, I; ALESSI, M.-C.STV. Sang thrombose vaisseaux. 1993, Vol 5, Num 7, pp 447-453, issn 0999-7385Article

Increased plasma plasminogen activator inhibitor 1 levels. A possible link betwwen insulin resistance and atherothrombosisJUHAN-VAGUE, I; ALESSI, M. C; VAGUE, P et al.Diabetologia (Berlin). 1991, Vol 34, Num 7, pp 457-462, issn 0012-186XArticle

Anticoagulant acquis antifacteur V : nosologie, risque hémorragique et prise en charge thérapeutique à propos de trois observations = Acquired factor V inhibitor : aetiology, bleeding risk and treatment with regard to three casesSCHLEINITZ, N; VEIT, V; CHOUQUET, D et al.La Revue de médecine interne (Paris). 2001, Vol 22, Num 11, pp 1119-1123, issn 0248-8663Article

Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factorsJUHAN-VAGUE, I; RENUCCI, J. F; GRIMAUX, M et al.Arteriosclerosis, thrombosis, and vascular biology. 2000, Vol 20, Num 9, pp 2156-2161, issn 1079-5642Article

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations a family study with part of the Stanislas cohortHENRY, M; TREGOUËT, D. A; ALESSI, M. C et al.Arteriosclerosis, thrombosis, and vascular biology. 1998, Vol 18, Num 1, pp 84-91, issn 1079-5642Article

Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex relationship to elevated TPA antigen in patients with high PAI-1 activity levelsCHANDLER, W. L; ALESSI, M. C; AILLAUD, M. F et al.Circulation (New York, N.Y.). 1997, Vol 96, Num 3, pp 761-768, issn 0009-7322Article

Characterization of epitheloid cells from human omentum : comparison with endothelial cells from umbilical veinsLATRON, Y; ALESSI, M. C; GEORGE, F et al.Thrombosis and haemostasis. 1991, Vol 66, Num 3, pp 361-367, issn 0340-6245Article

The increased plasma Lp(a) : B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysisALESSI, M. C; PARRA, H. J; JOLY, P et al.Clinica chimica acta. 1990, Vol 188, Num 2, pp 119-128, issn 0009-8981, 10 p.Article

Thrombose, fibrinolyse : résumés, Marseille, 2-3 décembre 1988 = Thrombosis and fibrinolysis: abstracts, Marseille, 2-3th December 1988JUHAN-VAGUE, I; AILLAUD, M. F; ALESSI, M. C et al.Thrombose, fibrinolyse. Réunion. 1988, 68 p.Conference Proceedings

C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat dietPOGGI, M; BASTELICA, D; BURCELIN, R et al.Diabetologia (Berlin). 2007, Vol 50, Num 6, pp 1267-1276, issn 0012-186X, 10 p.Article

Adipose tissue expression of gelatinases in mouse models of obesityLIJNEN, H. R; MAQUOI, E; HOLVOE, P et al.Thrombosis and haemostasis. 2001, Vol 85, Num 6, pp 1111-1116, issn 0340-6245Article

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood levelMORANGE, P. E; ALESSI, M. C; VERDIER, M et al.Arteriosclerosis, thrombosis, and vascular biology. 1999, Vol 19, Num 5, pp 1361-1365, issn 1079-5642Article

New direct assay of free protein S antigen applied to diagnosis of protein S deficiencyAILLAUD, M. F; POUYMAYOU, K; BRUNET, D et al.Thrombosis and haemostasis. 1996, Vol 75, Num 2, pp 283-285, issn 0340-6245Article

Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopeniaAMIRAL, J; MARFAING-KOKA, A; WOLF, M et al.Blood. 1996, Vol 88, Num 2, pp 410-416, issn 0006-4971Article

Acrosyndrome révélateur d'un déficit en protéine S au cours de l'infection par le virus de l'immunodéficience humaine = Acrosyndrom revealing a protein S deficit in HIV infectionPOIZOT-MARTIN, I; AQUILINA, C; BOUABDALLAH, R et al.Annales de médecine interne (Paris). 1992, Vol 143, Num 2, pp 109-112, issn 0003-410XArticle

Correlations between t-PA and PAI-l antigen and activity and t-PA/PAI-l complexes in plasma of control subjects and of patients with increased t-PA or PAI-l levelsALESSI, M. C; JUHAN-VAGUE, I; DECLERCK, P. J et al.Thrombosis research. 1990, Vol 60, Num 6, pp 509-516, issn 0049-3848, 8 p.Article

Bénéfice d'une dose de charge de 600 mg de clopidogrel sur les paramètres plaquettaires chez les patients admis pour syndrome coronaire aigu = Beneficial effect of a loading dose of 600mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndromeCUISSET, T; FRERE, C; QUILICI, J et al.Archives des maladies du coeur et des vaisseaux. 2006, Vol 99, Num 10, pp 889-893, issn 0003-9683, 5 p.Article